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A B S T R A C T
15-lipoxygenase-1 (15-LOX-1) oxygenates linoleic acid to 13(S)-hydroxyoctadecadienoic acid (HODE). The en-
zyme is widely suppressed in different cancers and its re-expression has tumor suppressive effects. 15-LOX-1 has
been shown to inhibit neoangiogenesis in colorectal cancer (CRC); in the present study we confirm this phe-
nomenon and describe the mechanistic basis. We show that re-expression of 15-LOX-1 in CRC cell lines resulted
in decreased transcriptional activity of HIF1α and reduced the expression and secretion of VEGF in both nor-
moxic and hypoxic conditions. Conditioned medium (CM) was obtained from CRC or prostate cancer cell lines
re-expressing 15-LOX-1 (15-LOX-1CM). 15-LOX-1CM treated aortic rings from 6-week old C57BL/6 mice showed
significantly less vessel sprouting and more organized structure of vascular network. Human umbilical vein
endothelial cells (HUVECs) incubated with 15-LOX-1CM showed reduced motility, enhanced expression of in-
tercellular cell adhesion molecule (ICAM-1) and reduced tube formation but no change in proliferation or cell-
cycle distribution. HUVECs incubated with 13(S)-HODE partially phenocopied the effects of 15-LOX-1CM, i.e.,
showed reduced motility and enhanced expression of ICAM-1, but did not reduce tube formation, implying the
importance of additional factors. Therefore, a Proteome Profiler Angiogenesis Array was carried out, which
showed that Thrombospondin-1 (TSP-1), a matrix glycoprotein known to strongly inhibit neovascularization,
was expressed significantly more in HUVECs incubated with 15-LOX-1CM. TSP-1 blockage in HUVECs reduced
the expression of ICAM-1 and enhanced cell motility, thereby providing a mechanism for reduced angiogenesis.
The anti-angiogenic effects of 15-LOX-1 through enhanced expressions of ICAM-1 and TSP-1 are novel findings
and should be explored further to develop therapeutic options.
1. Introduction
15-LOX-1 is a non-heme dioxygenase that preferentially metabolizes
the essential polyunsaturated fatty acid (PUFA) linoleic acid into 13-
(S)-hydroxyeicosatetraenoic acid (13(S)-HODE). 15-LOX-1 has been
shown to be universally lost in many different cancer cell lines [1],
primarily through epigenetic mechanisms [2]. Re-expression of the
gene has been shown to ameliorate a number of hallmarks of cancer
[3–5].
Angiogenesis is a complex multistep process involving degradation
of the extracellular matrix, migration and proliferation of endothelial
cells (EC) and their reorganization into tube like structures. In adults,
blood vessels are generally quiescent; ECs, however, are highly plastic
cells that can respond to different angiogenic cues to initiate new blood
vessel formation, thereby playing a crucial role in tumor growth and
metastasis [6,7]. Tumor associated blood vessels are generally ab-
normal in both structure and function. The sprouting is chaotic; the ECs
lack the typical cobblestone-like appearance and perfuse the tumor in a
disorderly manner [7]. Previous studies have indicated that expression
of 15-LOX-1 in prostate cancer (PCa) resulted in a pro-angiogenic effect
[8]. On the other hand, anti-angiogenic effects of 15-LOX-1 have also
been documented in rabbit skeletal muscle, rabbit eyes and mouse
retinal epithelia [9–11]. Re-expression of 15-LOX-1 in CRC cell lines
was shown to reduce the transcript levels of vascular endothelial
growth factor-A (VEGF-A) and reduce the stability of the transcription
factor hypoxia induced factor1α (HIF1α) [12].
In this study, we have aimed to mechanistically understand how 15-
LOX-1 expression in cancer cell leads to reduced angiogenesis. For this,
we have expressed 15-LOX-1 in two CRC cell lines, HCT-116 and SW-
480, and a prostate cancer cell line LNCaP. We observed that 15-LOX-1
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over-expression in the cancer cell lines resulted in reduced secretion of
angiogenic factors. Conditioned medium (CM) from these cells caused
several alterations in ECs, primarily in EC motility rather than pro-
liferation. This was corroborated by enhanced expression in ECs of in-
tercellular cell adhesion molecule (ICAM-1) that is known to enhance
the formation of EC polarity and proper directionality of movement
[13] and the antiangiogenic protein thrombospondin-1(TSP-1) that
inhibits neovascularization through reduced VEGF-A activity, enhanced
apoptosis of ECs, inhibition of EC migration, and suppression of nitric
oxide signaling [14].
2. Materials and methods
2.1. Cell culture, transfections and treatments
Human CRC cell line SW-480, LNCaP and the human vascular en-
dothelial cells (HUVECs) were obtained from ATCC (Middlesex,
England). HCT-116 cells were obtained from DSMZ (Braunschweig,
Germany). The epithelial cells were grown in RPMI-1640 (Biochrom,
Berlin, Germany) supplemented with 10% fetal bovine serum (FBS)
(Thermo Scientific, Waltham MA, USA), 2 mM L-glutamine and 1%
penicillin/streptomycin. HUVECs were grown on gelatin-coated plates
with EBM Endothelial Cell Medium (ECM) Bullet Kit (Lonza, Basel,
Switzerland) and used up to the 5th passage. All cell lines used were
authenticated at the University of Arizona, Genetics Core Facility,
Arizona, USA.
The stable transfection of HCT-116 with a 15-LOX-1-pcDNA3.1
vector for the expression of the human ALOX15 gene (kind gift from Dr.
Uddhav Kelavkar [8] or empty vector (EV) has been described by our
group previously [3,4,15]. Where indicated, two individual monoclones
stably expressing 15-LOX-1 were used. All stably transfected cells were
maintained in 125 μg/ml zeocin as the selection antibiotic. For the
transient expression of 15-LOX-1 in SW-480 or LNCaP cells, 7.5 × 105
cells per well were seeded in 6-well plates and transfected for 24 h with
X-tremeGENE HP (Roche, Mannheim, Germany) at a 1:1 ratio. The
medium was changed and the cells were then incubated for a further
48 h after which the cells and the conditioned medium (CM) were
collected. Each transfection was confirmed for 15-LOX-1 expression by
western blot. To collect CM from HCT-116 cells stably transfected with
the 15-LOX-1 plasmid, cells at 70–80% confluency were grown in
zeocin-free medium for 72 h, the medium was collected, centrifuged at
100 ×g for 10 min, aliquoted and stored at −80 °C until use. To grow
cells under hypoxia, a Hypoxia Incubator Chamber (Stemcell Technol-
ogies, Canada) was filled with a premixed gas containing 1% O2, 5%
CO2 and 94% N2 (confirmed with an oxygen sensor) and sealed. Before
starting the experiment, the cell culture medium was degassed over-
night. Flasks containing the degassed medium were placed in the
chamber, which was refluxed with the premixed gas after 1.5 h and
incubated for a total of 6 h. Preliminary experiments showed that there
was minimal cell death and a robust induction of VEGF-A after 6 h in
hypoxia. In each case, a parallel experiment was conducted under
normoxia for comparison.
Where indicated, HCT-116 cells stably transfected with a 15-LOX-1
vector or the corresponding EV were treated with 10 μM of the 15-LOX-
1 inhibitor PD146178, HUVECs were treated with 25 μM 13(S)-HODE
(Cayman Chemical, USA) or 100 ng/ml VEGF-A (Merck, Germany) for
24 h in complete medium.
2.2. 15-LOX-1 activity measurement
13(S)-HODE, the metabolic product of 15-LOX-1, was measured
with a competitive immunoassay kit (Enzo Life Sciences, USA) ac-
cording to the manufacturer's instructions. Briefly, 2 × 106 of HCT-116
cells stably transfected with 15-LOX-1 or EV were harvested, lysed, and
acidified with 0.2 N HCl. Organic phase from the samples was extracted
with water-saturated ethyl acetate. The extracts were dried completely
using benchtop Freeze Dry System (FreeZone 6 Liter, Labconco, USA).
Dried samples were dissolved in 25 μl ethanol, followed by 1:10 dilu-
tion with Assay Buffer. Samples were then applied to goat anti-rabbit
IgG microtiter plate, and the level of 13(S)-HODE was measured col-
orimetrically using a microplate spectrophotometer (Thermo Scientific,
USA) at 405 nm with correction at 580 nm. The 13(S)-HODE con-
centrations in the samples were determined from a standard curve.
2.3. RNA isolation, cDNA synthesis and RT-qPCR assays
Total RNA isolation was carried out by using RNeasy RNA
Extraction Kit (Qiagen, Hilden, Germany) according to the manufac-
turer's guidelines. cDNA synthesis from DNAse I (Thermo Scientific)
treated mRNA was carried out with 1 μg of the RNA using a RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientific).
RT-qPCR reactions were carried out in a Rotor GeneQ 6000
(Qiagen) using standard techniques. Fold changes were calculated with
respect to the internal control (β-Actin) using the Pfaffl method [16].
MIQE guidelines were followed in the RT-qPCR reactions [17]. The
primer sequences are shown in Supplementary Table 1.
2.4. VEGF secretion assay
The secreted VEGF-A165 levels in cell culture supernatants was
measured with the Quantikine Human VEGF Immunoassay kit (R & D
Systems, Minneapolis, MN, USA) according to the manufacturer's pro-
tocol.
2.5. Western blotting
Proteins (20–50 μg) were separated in 10% SDS-PAGE gels and
transferred to PVDF membranes using standard techniques. The anti-
bodies used are shown in Supplementary Table 2. Bands were visua-
lized with the Clarity ECL Substrate (Bio-Rad, Hercules, CA, USA) and
ChemiDoc MP Imaging System (Bio-Rad).
2.6. Luciferase assay
HCT-116 cells stably transfected with 15-LOX-1 or EV were plated
in 48-well plates (5 × 104 cells/well) and allowed to attach overnight.
After transfection with 300 ng of pGL3-5xHRE-VEGF-Luc (generous gift
from Dr. Ilias Mylonis) [18] and pRL-TK Renilla (Promega, Madison,
WI, USA) (Firefly:Renilla ratio of 250:1) using X-tremeGENE HP (1:2
plasmid:transfection reagent ratio), the cells were incubated under
hypoxia or normoxia for an additional 6 h. The luciferase assay was
conducted with the Dual-Luciferase Assay kit (Promega) according to
the manufacturer's instructions.
2.7. Mouse aorta ring assay
To determine the effect of 15-LOX-1CM on the sprouting ability of
endothelial cells, an ex vivo mouse aorta ring assay was carried out as
described previously [19]. The study was approved by the animal ethics
committee of Bilkent University (Decision no: 2014/36). Institutional
and national guidelines for the handling and care of animals were fol-
lowed. Aortas were removed from 6 to 8 weeks old C57BL/6 mice, cut
into 1.0 mm rings, embedded in Matrigel and incubated in 500 μl of a
1:1 mixture of CM and OptiMEM containing 2.5% FBS and 1% Pen/
Strep at 37 °C for 9 days. The medium was changed every other day.
The images acquired on the 9th day were analyzed using WimSprout
(Wimasis, Munich, Germany). Rings incubated in medium with 20%
FBS and 2.5% FBS served as positive and negative controls, respec-
tively. The experiment was repeated three times independently and
aortas from three different mice were used for each experiment.
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2.8. HUVEC tube formation assay
The tube formation assay was carried out using HUVECs embedded
in Matrigel in a 1:1 ratio of CM and ECM as described previously [20].
Where indicated, HUVECs were treated with 25 μM 13(S)-HODE in 1:1
ratio of RPMI-1640 complete growth medium and ECM. Cells were
incubated for 6 h and tubes were photographed with an inverted mi-
croscope (Olympus, Hamburg, Germany) or JuLi Smart Fluorescence
Cell Imager. The results were analyzed using WimTube (Wimasis).
2.9. HUVEC proliferation and cell cycle assay
Proliferation of HUVECs incubated in a 1:1 ratio of CM and ECM
was determined by an MTT assay. Briefly, 5 × 103 HUVECs were plated
in each well of a 96-well plate and allowed to attach overnight. The
MTT assay was conducted according to standard protocols.
Measurements were carried out at 570 nm in a plate reader (Thermo
Scientific).
For cell cycle analysis, HUVECs at 50% confluency were treated
with a 1:1 ratio of CM and ECM for 24 h. The cells were collected,
counted and 5 × 105 cells were fixed with 70% ethanol overnight at
−20 °C. The cells were washed with 1× PBS and incubated in a
staining solution containing 0.1% Triton-X (Applichem), 0.2 mg/ml
RNase (Thermo Scientific) and 15 μg/ml Propidium iodide (Sigma,
Taufikirchen, Germany) for 30 min in the dark at room temperature.
The cell cycle distribution was obtained from a flow cytometer (BD
Biosciences, Ann Arbor, MI, USA) and analyzed with the BD Accuri C6
software.
2.10. In vitro wound healing assay
Scratches were made with sterile 200 μl pipette tips in 100% con-
fluent HUVECs incubated with 1:1 ratio of CM and ECM or 25 μM
13(S)-HODE containing RPMI-1640 complete growth medium and ECM
for 15 h. Cells were photographed with a JuLi Smart Fluorescence Cell
Imager at 3 h intervals, a total of 9 h. Where indicated, followed by 18 h
incubation with 1:1 ratio of CM and ECM, blocking experiments for 6 h
with a TSP-1 or isotype specific IgG antibody were carried out.
2.11. Proteome profiler human angiogenesis array
HUVECs were incubated with a 1:1 ratio of CM and ECM for 24 h
and lysed in a buffer containing 1% NP-40, 20 mM Tris-HCl (pH 8.0),
137 mM NaCl, 10% glycerol, 2 mM EDTA and 1× protease inhibitor
cocktail (Roche). 200 μg of the lysate was used per membrane of a
Proteome Profiler Array, Human Angiogenesis Array Kit (R & D
Systems). Three independent angiogenesis arrays with three in-
dependent protein sets from two lots of HUVECs were conducted. After
visualizing the spots, the signals were measured with a Protein Array
Analyzer plugin for ImageJ (https://imagej.nih.gov/ij/). Intensity files
obtained from ImageJ were then uploaded to an in-house MATLAB code
(MATLAB R2016a and Statistics Toolbox 11.0, The MathWorks, Inc.,
Natick, MA, USA, code available upon request). Details on normal-
izations methods are available in Supplementary Fig. 6.
2.12. Bioinformatic data analyses
CEL files of GSE43133 were downloaded from NCBI GEO database
[21]. Samples labeled GSM1057218–23 belonging to CD47 wild-type or
null lung ECs of mice (C57Bl/6) were used in further analyses. gcrma R
package from bioconductor.org was used to perform robust multiarray
average (RMA) normalization [22]. For differential gene expression
analysis, limma package of bioconductor was used [23]. Genes differ-
entially expressed at p < 0.05 were determined; from these, genes that
belonged to the GO:0016477 Cell Migration term and GO:0007155 Cell
Adhesion term were downloaded from the BioMart facility of Ensembl
(release 84), AmiGO2 (version 2.5.5) and PANTHER (11.1) databases
[24–26]. Only those genes appeared in all three databases were used for
further analyses; Fisher's Exact test was performed for the significance
analysis of GO term enrichment (Matlab).
CEL files of GSE77199 datasets and the pre-processed data for
GSE2177 were downloaded from the NCBI GEO database [27,28]. For
GSE2177, data from GSM39408 (vehicle treated Human Microvascular
Endothelial Cells, HMVECs)) and GSM39409 (HMVECs treated with DI-
TSPa, a TSP mimetic peptide) were globally normalized and log
transformed to estimate the log fold change. For GSE77199, samples
labeled GSM2045928-GSM2045931 (healthy colon EC) and those la-
beled GSM2045932-GSM2045935 (CRC associated EC) were used.
limma [23] package was used for normalization and paired differential
expression analysis. We then performed principal components analysis
(PCA) for detecting outlier pair(s); accordingly, GSM2045934 and the
corresponding healthy sample, GSM2045930, that showed negative or
no correlation with other subjects were removed. Genes differentially
expressed at p < 0.05 were determined. Genes altered in the opposite
direction in GSE2177 and GSE77199 were used for identifying protein-
protein interactions (default setting) using STRING 10.0 [29,30]. Based
on STRING we then identified enriched GO Terms in the largest con-
nected component and the first five GO Terms were selected. If more
than one term belonged to the same ancestor only the ancestor term
was used. We plotted the network in Matlab using a color palette.
2.13. Statistical analyses
Results were expressed as the mean ± standard error of mean
(SEM). Data analyses and graphing were carried out with GraphPad
Prism 6.0. Two-way ANOVA, Student's t-tests or limma were used for
statistical analysis, and differences at p≤ 0.05 were considered sig-
nificant. When more than a single factor was present a Two-way
ANOVA also was applied to test for the main and interaction effects.
Experiments were repeated independently at least three times with at
least three technical replicates.
3. Results
3.1. 15-LOX-1 expression in cancer cell lines reduced VEGF expression and
secretion
The cell lines used in this study did not express any 15-LOX-1 within
the detection limits of a western blot. HCT-116 cells stably transfected
(clones 1 and 2) and SW-480 and LNCaP cells transiently transfected
with the 15-LOX-1 plasmid resulted in robust expression of the 15-LOX-
1 protein compared to the EV transfected control cells (Fig. 1A, Sup-
plementary Fig. 1A, B). The enzymatic activity of 15-LOX-1 in stably
transfected HCT-116 cells was confirmed by a 13(S)-HODE ELISA kit
(Fig. 1B).
VEGF-A (commonly referred to as VEGF) is strongly implicated in
angiogenesis [31]. We observed a significant reduction in mRNA ex-
pression of VEGF in 15-LOX-1 expressing HCT-116 (clones 1 and 2,
Fig. 1C), SW-480 cells (Supplementary Figure Fig. 1C) and LNCaP cells
(Supplementary Fig. 1D). Moreover, when the 15-LOX-1 expressing
HCT-116 cells (clone 1) were treated with PD146176 (a 15-LOX-1 in-
hibitor that reduces the synthesis of 13(S)-HODE [3]), we observed a
recovery of VEGF mRNA expression to a level comparable with the EV
transfected cells (Fig. 1F). Angiogenesis is generally activated in a hy-
poxic tumor environment, which leads to the stabilization of tran-
scription factors called hypoxia inducible factors (HIFs) that can then
upregulate VEGF expression [7]. 15-LOX-1 mediated reduction in VEGF
mRNA levels was retained even under hypoxia (Fig. 1D, Supplementary
Fig. 1C). The reduced VEGF expression in 15-LOX-1 expressing cells
was accompanied by a reduction in VEGF secretion under both hypoxic
and normoxic conditions (Figs. 1E, Supplementary Fig. 1C, D). A luci-
ferase construct containing 5 copies of the HIF1α binding sequence in
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the VEGF promoter showed reduced activity in the 15-LOX-1 expressing
cells in both hypoxic and normoxic conditions (Fig. 1G).
3.2. Conditioned medium obtained from 15-LOX-1 expressing cells reduced
angiogenic sprouting and tube formation
Paracrine factors released from tumor cell can affect angiogenic
signaling [31,32]. To examine this, we carried out an ex vivo aortic ring
assay where, in the presence of appropriate signals, quiescent ECs in the
aorta are activated to form organized sprouts. Aortas incubated with
15-LOX-1CM showed reduced sprouting and pseudocapillary tubes as
well as lower sprout area and sprout length. The mean ring areas of the
aortas incubated with the 15-LOX-1CM versus the EVCM were similar,
indicating that the differences observed in sprouting were unrelated to
the ring area (Fig. 2A).
We next incubated HUVECs in a 1:1 mixture of CM from stably 15-
LOX-1 transfected HCT-116 cells and ECM. Significantly lower tube
length and total number of tubes along with fewer branches and loops
were seen in HUVECs incubated with 15-LOX-1CM from HCT-116 cells
compared to the control EVCM (Fig. 2B). These differences became
even more pronounced when the HUVECs were incubated in CM col-
lected after maintaining the cells under hypoxia for 6 h. Similar changes
Fig. 1. 15-LOX-1 expression in HCT-116 colon cancer cells reduces VEGF transcription and secretion (A) 15-LOX-1 was re-expressed stably in HCT-116 (monoclone 1 and monoclone 2)
and 15-LOX-1 expression was determined by Western blotting. (B) 13(S)-HODE level was significantly increased in stably 15-LOX-1 expressing cells, with respect to EV transfected cells.
(C) VEGF mRNA levels in 15-LOX-1 stably transfected HCT-116 cells (monoclone 1 and monoclone 2) were analyzed by RT-qPCR relative to stably empty vector (EV) transfected cells
(n= 4). (D) VEGF transcription in 15-LOX-1 stably transfected HCT-116 cells under normoxic and hypoxic conditions was determined by RT-qPCR. Quantification was carried with
respect to normoxic EV transfected cells (n= 4). (E) Histograms show a reduction in secreted VEGF levels under normoxic and hypoxic conditions in stably 15-LOX-1 compared to EV
transfected HCT-116 cells (n = 3). (F) RT-qPCR showing that reduced expression of VEGF mRNA in HCT-116 cells stably expressing 15-LOX-1 was lost when the cells were treated with
the specific 15-LOX-1 inhibitor PD146176. Fold-changes in gene expression are given relative to EV transfected and DMSO vehicle (Veh.) treated cells (n = 4). (G) Dual-luciferase assay
showed reduced VEGF promoter activity in HCT-116 cells stably expressing 15-LOX-1 under both normoxic and hypoxic conditions (n = 3). Firefly luciferase activities were normalized
to Renilla luciferase activities, and the results were represented as fold change respect to EV transfected HCT-116 cells under normoxia. Quantification was carried with respect to EV
transfected cells. All results were analyzed with t-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
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Fig. 2. 15-LOX-1 expression in colon cancer epithelial cells reduces angiogenesis (A) Ex vivo mouse aorta ring explant assay. The aorta rings were incubated with conditioned medium
(CM) from stably transfected 15-LOX-1 or control (EV) cells for 9 days. Sprouts structure (blue), sprouts front (red) and the aorta ring (orange) were marked (WimSprout, Wimasis). Aortic
ring area parameter shows the area of the original explant before the sprouting occurs. Representative images from three independent aorta assays are shown. (B) Tube formation assay.
HUVECs were incubated on Matrigel for 6 h with 15-LOX-1CM or EVCM under normoxic or hypoxic conditions. The number of tubes (red) and loops (yellow), branching points (white)
and total tube length parameters were determined (WimTube, Wimasis). (C) Representative images demonstrate dense vessels sprouting from an aorta ring incubated with CM from EV
(upper left); this network was lost when the aorta was incubated in 15-LOX-1CM (lower right). Complex mesh formation seen with HUVECs grown in CM from control cells (lower left)
was reduced when the cells were incubated in 15-LOX-1CM (lower right). Statistical significance was determined by t-test (*p ≤ 0.05, **p ≤ 0.01). (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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were observed with CM obtained from SW-480 cells and LNCaP cells
expressing 15-LOX-1 (Supplementary Fig. 2A and B).
Overall, we observed that secreted factors from 15-LOX-1 expres-
sing cells resulted in a reduced ability of ECs to sprout and form tubes
both ex vivo and in vitro. Moreover, mouse aorta rings incubated with
EVCM showed a rather dense and chaotic network with irregular
branching pattern, most likely representing collateral vessels [33]. This
network was lost in the rings incubated with 15-LOX-1CM (Fig. 2C,
upper panel). Additionally, complex mesh formation [36], which are
large rounded structures with walls that are four to five cells thick were
seen in the HUVECs incubated with EVCM (Fig. 2C, lower panel) but
not in the HUVECs incubated with 15-LOX-1CM. These findings in-
dicated the possibility that secreted factors in 15-LOX-1CM may result
in the normalization of tumor vasculature. Tumor associated en-
dothelial cells (TECs) have abnormal branching morphogenesis and
sprout excessively [33]. We first established that tumor conditioned
HUVECs could display TEC characteristics. We grew HUVECs in a 1:1
mixture of ECM and CM from wild-type HCT-116 cells and observed a
2–2.5 fold increase in the expression of Fibroblast Associated Protein-α
(FAP) (Supplementary Fig. 3A), a well-established TEC marker [34,35].
We observed significant, albeit modest decreases in the expression of
the TEC markers Protein Regulator of Cytokinesis 1 (PRC-1) [37] and
ADAM Metallopeptidase Domain 23 (ADAM23) [34] in HUVECs in-
cubated with 15-LOX-1CM compared to the control cells (Supplemen-
tary Fig. 3B).
3.3. Conditioned medium obtained from 15-LOX-1 expressing cells reduced
motility of HUVECs
ECs were incubated in 15-LOX-1CM and analyzed for proliferation,
cell cycle and motility. Interestingly, we did not observe any alteration
in the proliferation of HUVECs incubated with 15-LOX-1CM from either
HCT-116 or SW-480 cells, indicating that reduced tube formation was
unrelated to proliferation (Fig. 3A). Corroborating these data, cell cycle
analysis of HUVECs incubated with either 15-LOX-1CM or EVCM from
HCT-116 cells did not result in significant alterations in cell cycle stages
(Supplementary Fig. 4). On the other hand, a scratch wound healing
assay showed significantly decreased motility of HUVECs when the cells
were incubated with 15-LOX-1CM from HCT-116 compared to EVCM
(Fig. 3B). We next probed the cells for expression of cell adhesion
markers and observed an increase in the expression of ICAM-1 (Fig. 3C,
Supplementary Fig. 5 for 15-LOX-1CM from LNCaP cells) and a de-
crease in the expression of the mesenchymal marker Vimentin (Fig. 3C)
in HUVECs treated with 15-LOX-1CM compared to the control EVCM
treated cells. No change was observed in the expression of VCAM-1.
These data indicate that 15-LOX-1CM could reduce the motility of the
cells, without affecting their proliferation or cell cycle distribution.
3.4. Incubation of EC's with 13(S)-HODE phenocopied most, but not all
features of 15-LOX-1CM treatment
15-LOX-1 overexpression in cells leads to an enhanced production of
13(S)-HODE from the substrate linoleic acid. This bioactive lipid has
previously been shown to affect endothelial cell characteristics in
models of atherosclerosis [34] as well as cancer [12]. Incubation of
HUVECs with a 1:1 mixture of ECM and complete RPMI-1640 con-
taining 25 μM 13(S)-HODE led to reduced motility in a scratch wound
assay (Fig. 4A) and remarkably enhanced expression of ICAM-1
(Fig. 4B), but did not lead to any alteration in tube formation (Fig. 4C).
Therefore, additional inhibitory factors in the tumor microenvironment
are likely to contribute to the reduced tube formation observed with 15-
LOX-1CM.
3.5. Proteome profiler array analysis in HUVECs incubated with 15-LOX-
1CM
To define any additional factors that may contribute to reduced
angiogenesis and potential vascular normalization observed with 15-
LOX-1CM, we examined the expression of 55 angiogenesis related
proteins. A Proteome Profiler Array was used with protein lysates from
Fig. 3. Effect of conditioned medium (CM) from 15-LOX-1 expressing colon cancer epithelial cells on endothelial cell proliferation and motility (A) HUVECs were incubated with CM from
HCT-116 stably expressing 15-LOX-1 or transiently transfected SW-480 cells for 24 h, and viability of HUVECs was determined by MTT assay. Cell survival is represented as percent
respect to EVCM (control) treated cells. (B) Scratch assay shows the time dependent migration capacities of HUVECs treated with CM obtained from stably 15-LOX-1 or EV expressing
HCT-116 cells. Two-way ANOVA was used to compare the means (*p ≤ 0.05, ***p≤ 0.001). (C) Western blot showing the expression of ICAM-1, VCAM-1 and vimentin in HUVECs
treated with 15-LOX-1CM or EVCM. Statistical significance was determined by t-test (*p≤ 0.05).
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HUVECs incubated with 15-LOX-1CM from HCT-116 cells or EVCM
(Supplementary Fig. 6A). Our analyses revealed that correlation be-
tween the duplicate spots was very strong for all arrays indicating the
high quality of the experiments (Supplementary Fig. 6B). When un-
normalized (Supplementary Fig. 6C), and even after global normal-
ization (Supplementary Fig. 6D) data distribution within each batch of
the array sets (experiment vs. control for experiments 1–3) were more
similar to each other than in between sets. Batch correction performed
by subtracting the control spot value from that of the corresponding
experiment spot normalized the arrays further and made them more
comparable (Supplementary Fig. 6E). A significant increase in the
protein levels of Thrombospondin-1 (TSP-1) was observed (Fig. 5A; t-
test p = 0.044) in HUVECs incubated with 15-LOX-1CM. The sig-
nificant increase was further confirmed at both the protein and mRNA
levels from HUVECs incubated with 15-LOX-1CM compared to EVCM
(Fig. 5B).
To understand whether the altered expression of TSP-1 in HUVECs
treated with 15-LOX-1CM was due to the enhanced secretion of 13(S)-
HODE, we treated HUVECs with 25 μM 13(S)-HODE, but did not ob-
serve a significant change in the expression of TSP-1 (Fig. 5C). On the
other hand, treatment of HUVECs with 100 ng/ml recombinant human
VEGF resulted in a significant decrease in the expression of TSP-1
(Fig. 5D). It is therefore likely that the enhanced expression of TSP-1
observed in HUVECs treated with 15-LOX-1CM was due to the reduced
secretion of VEGF by the 15-LOX-1 re-expressing cancer cells.
3.6. Signaling mechanism associated with decreased motility of HUVECs
incubated with 15-LOX-1CM
We next aimed to address the signaling mechanism resulting from
enhanced levels of TSP-1 in endothelial cells incubated with CM from
15-LOX-1 expressing cells. TSP-1 primarily binds to CD47 and CD36 as
the cognate receptors for further downstream signaling [35]. Large
vessel ECs express little or no CD36 [36]; we have observed con-
siderably lower expression of CD36 when compared to CD47 in the
HUVECs used in the current study (Supplementary Fig. 7A). No dif-
ference in the expression of CD47 was observed when the HUVECs were
treated with either 15-LOX-1CM or EVCM (Supplementary Fig. 7B).
Additionally, TSP-1, by binding to CD36, can inhibit signaling through
VEGFR2 [37]. We observed no change in the phosphorylation of
VEGFR2 (Tyr 1175) in HUVECs treated with 15-LOX-1CM (Supple-
mentary Fig. 7C). It is thus likely that TSP-1 mediates its effects via
CD47 in the model examined in the current study. Based on this, we
explored a publicly available microarray data from ECs of a CD47 null
mouse model (GSE43133). The expression of 20.6% and 20.8% of all
genes associated with GO terms migration (Fisher Exact test
p = 3.38e−04) and adhesion (Fisher Exact test p= 1.29e−08), re-
spectively, were altered in these cells (Fig. 6A) compared to 16% of
altered genes in the entire dataset. In mice, ICAM-1 was significantly
downregulated with the loss of CD47 in the ECs (Fig. 6B; p = 0.0008).
When we examined the levels of ICAM-1 in the HUVECs incubated with
15-LOX-1CM for 24 h, we observed a significant upregulation in ICAM-
1 (Fig. 6C; p ≤ 0.05). More importantly, when these cells were also
incubated with a TSP-1 blocking antibody for 6 h, we observed a sig-
nificant decrease in the levels of ICAM-1 at both mRNA and protein
levels (Fig. 6C) indicating that the increase in ICAM-1 was also medi-
ated through TSP-1 signaling. To functionally determine whether TSP-1
blocking could affect EC motility, we carried out a scratch wound
healing assay where TSP-1 mediated signaling was inhibited with a
blocking antibody or an isotype specific IgG antibody. In the HUVECs
incubated with EVCM, blocking of TSP-1 resulted in a significantly
greater motility of the cells compared to HUVECs incubated with IgG
(Fig. 6D). Of note, recovery in motility to a similar extent was also seen
in the HUVECs incubated with 15-LOX-1CM and TSP-1 blocking anti-
body (p = 0.2592, two-way ANOVA with anovan in Matlab). The
overall motility of HUVECs incubated in 15-LOX-1CM was low in-
dicating that factors in addition to TSP-1 in the CM may also have
contributed to the reduced motility seen in these cells.
HUVECs incubated with 15-LOX-1CM showed a potential vascular
normalization (Fig. 2C). To determine whether this event was related to
Fig. 4. 13(S)-HODE reduces motility and enhances ICAM-1 expression in endothelial cells (A) Incubation of HUVECs with 13(S)-HODE led to reduced motility in a scratch wound assay.
Two-way ANOVA was used to compare the means (*p≤ 0.05). (B) 13(S)-HODE treatment of HUVECs enhanced expression of ICAM-1 in RT-qPCR (n = 3). Fold-change in gene
expression is given relative to ethanol vehicle (Veh.) treated cells. Statistical analysis was carried out using t-test (*p ≤ 0.05). (C) Tube formation parameters did not change in 13(S)-
HODE treated HUVECs.
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the expression of TSP-1, we used bioinformatics tools to compare genes
that were significantly downregulated in a microarray dataset from
human microvascular endothelial cells (HMVECs) treated with a TSP-1
mimetic peptide [21] with genes that were significantly upregulated in
human tumor associated endothelial cells from CRC [28]. A group of 54
intersect genes were significantly inversely correlated. STRING 10.0
analysis identified significant protein-protein interaction (PPI) enrich-
ment (p < 0.00153, data not shown) with one high density cluster
(Supplementary Fig. 8). Functional enrichment in processes related to
migration, morphogenesis and locomotion were identified.
4. Discussion
15-LOX-1 expression is widely suppressed in CRC, primarily through
epigenetic mechanisms [2]. Re-expression of the protein in different
cancer models has been shown to negate several hallmarks of cancer,
including angiogenesis [38,39]. Here, we aimed to understand the
mechanism through which 15-LOX-1 re-expression in CRC cell lines
inhibited angiogenesis in endothelial cells.
New vessel formation is essential for a tumor to grow; limiting new
vessel formation is widely considered to be an effective therapeutic tool
in cancer [40]. The reduced transcription, expression and secretion of
VEGF, a growth factor that is primarily responsible for angiogenesis,
was observed with 15-LOX-1 overexpression in different cancer cell
lines from different organs in the current study. This corroborates with
data shown previously in both cancer [39,41] and non-cancer models
[9,42]. We did not observe any alterations in the activation (phos-
phorylation) of VEGF receptors in both HCT-116 and LNCaP cells ex-
pressing 15-LOX-1 (data not shown), indicating that rather than auto-
crine signaling, paracrine signaling between tumor cells and ECs in the
tumor microenvironment may be functional in this model. Supporting
this, we observed that 15-LOX-1CM could reduce sprouting in an ex vivo
aorta ring assay as well as a HUVEC tube formation assay. Tumor
vessels are known to be chaotic in their organization with tortuous
structures that may be irregular, multilayered and poorly inter-
connected [7]. There has been a consensus in recent years that re-
storation of normal vascular architecture may enhance the success of
chemotherapy [7]. We observed an obvious reduction in the formation
of collateral vessels in the aortic rings and mesh structure in the tube
formation assay in the presence of 15-LOX-1CM, indicating a potential
reduction in the complexity of the structures.
Angiogenesis characteristically includes EC mitosis, extracellular
matrix remodeling and sprouting [33]. We did not observe any changes
in the proliferation or cell cycle distribution of HUVECs incubated with
15-LOX-1CM or EVCM. Significant inhibition, however, was observed
in the motility of HUVECs incubated with 15-LOX-1CM. Mechan-
istically, this was through reduced expression of vimentin, a mesench-
ymal marker that is essential for cell motility [43].
Fig. 5. Proteome Profiler Array for Angiogenesis showing a significant increase in the expression of TSP-1 in HUVECs treated with 15-LOX-1 conditioned medium (A) Spot intensities from
a representative image showing TSP-1 expression in HUVECs treated with 15-LOX-1CM or EVCM from HCT-116 cells (upper panel). Change in the expression is given as log2 fold change
calculated after normalizations (lower panel). (B) Representative Western blot showing TSP-1 expression in HUVECs treated with 15-LOX-1CM (HCT-116) or EVCM 24 h (upper panel).
Western blot results are given as quantitative densitometry of five independent experiments (lower right). Increase in TSP-1 expression in 15-LOX-1CM treated HUVECs was also shown
by RT-qPCR (n= 3) (lower left). Statistical significance was determined by t-test (*p ≤ 0.05, **p ≤ 0.01). (C) TSP-1 mRNA levels did not change significantly in 13(S)-HODE treated
HUVECs (n= 3). (D) RT-qPCR shows decreased TSP-1 expression VEGF treated cells, respect to vehicle (Veh.) control (n = 4). t-Test was used for data analyses (*p ≤ 0.05).
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ECs interact with leukocytes with the help of cell adhesion mole-
cules such as ICAM-1 [44]. The expression of cell adhesion molecules in
tumor associated endothelial cells (TECs) have been previously shown
to be reduced epigenetically through histone modifications via growth
factors secreted by tumor cells [45]. This growth factor induced re-
duction in cell adhesion molecules, including ICAM-1, has been shown
to reduce leukocyte infiltration in mouse ECs. This process, called en-
dothelial cell anergy, results in reduced immune cell recruitment to the
tumor microenvironment and enhanced tolerance [46]. We have ob-
served a decrease in VEGF expression and secretion in epithelial cells
expressing 15-LOX-1 and an increase in the expression of ICAM-1 in the
HUVECs treated with 15-LOX-1CM from both colon and prostate cancer
cell lines. These data imply that the 15-LOX-1CM treated HUVECs may
be able to mitigate endothelial cell anergy.
We next examined whether the product of 15-LOX-1 enzymatic
activity, 13(S)-HODE, can phenocopy the anti-angiogenic effects or 15-
LOX-1. We observed that ECs treated with 13(S)-HODE alone resulted
in reduced cell motility and enhanced the expression of ICAM-1. This
was expected, since enhanced expression of ICAM-1 in the presence of
13(S)-HODE has been reported in atherosclerotic lesions [47].
Fig. 6. TSP-1 signaling through CD47 regulates HUVEC adhesion, migration and motility (A) Compartmentalization of genes from GSE43133 labeled with GO terms Cell Migration (131
out of 635 migration related genes, Fisher Exact test p = 3.38e−04) and Cell Adhesion (249 out of 1194 genes, Fisher Exact test p = 1.29e−08) in CD47 null ECs (B) Reduced
expression of ICAM-1 (log2 fc = −2.1249; p = 0.00084) was seen in CD47 null ECs in GSE43133 (C) Western blot analysis of ICAM-1 in HUVECs treated with CM from 15-LOX-1 or EV
stably expressing HCT-116 cells for 24 h. Co-incubation of these cells with a TSP-1 blocking antibody resulted in a significant decrease in ICAM-1 mRNA levels, analyzed by RT-qPCR
(n= 3). ICAM mRNA levels were calculated respect to EVCM, and represented as fold change. t-test was used for data analyses (*p≤ 0.05). (D) Scratch wound assay showing that TSP-1
blocking resulted in a recovery of motility to a similar extent (p = 0.2592, Two-way ANOVA) in both EVCM and 15-LOX-1CM treated cells (n = 3). The motility of 15-LOX-1CM treated
cells was in general low indicating that factors in addition to TSP-1 may also be functional. Statistical significance was determined by t-test (*p ≤ 0.05, **p ≤ 0.01, **p ≤ 0.001).
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However, more importantly, 13(S)-HODE did not affect the tube for-
mation ability of HUVECs. This indicated the importance of a tumor
microenvironment and presence of tumor associated factors in addition
to13(S)-HODE in the current model.
An angiogenesis specific proteome array was therefore carried out
and a significant and reproducible increase in TSP-1 expression was
observed in HUVECs incubated with 15-LOX-1CM. The increase in TSP-
1 expression was confirmed at both mRNA and protein levels in
HUVECs treated with 15-LOX-1CM from HCT-116 cells. TSP-1 is a
member of the thrombospondin family and was the first endogenous
anti-angiogenic protein discovered [35]. TSP-1 inhibits angiogenesis by
vasoconstriction through the inhibition of nitric oxide signaling [48].
VEGF signaling has been shown to reduce the expression of TSP-1
through the upregulation of miR-17-92 cluster [49]; we observed that
treatment of HUVECs with 100 ng/ml VEGF reduced the expression of
TSP-1. It is therefore feasible that the reduced secretion of VEGF in the
microenvironment of 15-LOX-1 expressing cancer cells may have con-
tributed towards the enhanced expression of TSP-1 in ECs.
TSP-1 is known to signal in an autocrine manner through its re-
ceptor CD47 [50] and affect EC migration and adhesion [51]. Analysis
of microarray data from CD47 null primary lung ECs indicated statis-
tically significant alterations in GO terms related to migration and ad-
hesion. ICAM-1 has been shown to be upregulated after the engagement
of TSP-1 to CD47 in HUVECs [52] and human brain microvascular ECs
[53]. Corroborating this, we observed a significant decrease in ICAM-1
in CD47 null mouse lung ECs from microarray data and an increase in
the expression of ICAM-1 in HUVECs treated with 15-LOX-1CM, which
was reversed when the cells were treated with a TSP-1 blocking anti-
body.
The TSP-1 interactome is enriched in ligands that are involved in
extracellular matrix remodeling, cell- extracellular matrix interaction,
cell-cell adhesion, motility and vascular normalization [52–54].
Pathway analysis of TECs in colorectal tumors compared to angiogenic
(placental) and non-angiogenic ECs [55] indicated an enrichment of
genes that are functional in cytoskeleton organization and extracellular
matrix remodeling. This is highly reminiscent of the pathways altered
in the current study. We therefore explored, using bioinformatics tools,
whether TSP-1 signaling was involved in tumor vessel normalization.
Common genes that were significantly downregulated in ECs treated
with a TSP-1 mimetic and upregulated in CRC TECs were enriched for
motility, further emphasizing the importance of TSP-1 mediated sig-
naling in reducing EC motility, thereby enhancing normalization.
In conclusion, we have shown here that 15-LOX-1 expression in
colon and prostate cancer cells leads to reduced angiogenesis.
Alterations in pathways such as motility and adhesion were highly
represented in our model and are likely to be among the major me-
chanisms for reduced angiogenesis observed when 15-LOX-1 is ex-
pressed in CRC cells. Mechanistically, we have shown for the first time
that these changes could be mediated by an increase in the expression
of both ICAM-1 and the anti-angiogenic protein TSP-1 (Fig. 7). The
proteome array used in the current study is not all inclusive, involving
only 55 proteins that play a role in angiogenesis. It is therefore likely
that future studies will provide further mechanisms and pathways that
may be activated as a result of 15-LOX-1 expression in CRC cells.
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